Ocular Drug
Delivery Systems
Cefta-OcuExtend® for sustained delivery of ceftazidime in the eye
A single-dose administration of the inserts maintains drug levels for 4 days
Dual drug-loaded AmiVan-OcuExtend® for Ophthalmic sustained delivery of Amikacin/ Vancomycin
one insert every 5 days
GenPred-OcuExtend® Antibacterial/Anti-inflam matory Dual Drug-Loaded fibrous Inserts for Ophthalmic Sustained Delivery of Gentamicin and Methylprednisolone
With a single-dose performance for 9 days of drug release in the eye.
Oflo-OcuExtend ® sustained Release of Ofloxacin
Effectively maintained the drug concentration in the tear fluid for up to 4days.
Ery-OcuExtend® for Controlled Delivery of Erythromycin
A single dose maintains ERY levels in tear fluid for 4 days
CIP-OcuExtend® for Sustained Ocular Delivery of Ciprofloxacin Hydrochloride
Long-term and slow release of ciprofloxacin from inserts for 5 days
Azi-OcuExtend® for Sustained Ocular Delivery of Azitromycine
Release of drug in tear fluid for approximately 6days from
‘RDN Innovating Drug Design and Development
RDN is a startup specializing in the research and development of novel pharmaceutical products, with a particular focus on ophthalmic and dental applications.
Currently, Rahesh Darou Novin is completing the clinical studies for the OcuExtend®' system. studies will continue until the approval for entry into the human pharmaceutical market is obtained.
OcuExtend®
- "RDN not only pioneers ocular drug delivery studies but also extends a helping hand to homeless animals by providing them with essential medical care.
- OcuExtend® places the utmost importance on animal welfare and respecting the rights of all living creatures. In all of our reported research studies, no animals were harmed or killed. Animal welfare and ethical considerations have been at the forefront of our work throughout the research and development process.
- Respect for animals is important to OcuExtend® , and in all reported studies, no animals were killed. Animal rights have been considered throughout our research
OcuExtend®
Rahesh Darou Novin, a pioneering research and development company, is at the forefront of innovative ocular drug delivery products under the brand 'OcuExtend®'
Rahesh Darou Novin’s OcuExtend® systems can administer medication for 3-30 days with a single application. These systems do not require anesthesia or sedation for administration
OcuExtend®
"Over more than 45 research and development studies on OcuExtend® Drug Delivery Systems, it has been shown that these systems can be used for domestic animals, pets, and stray animals."
OcuExtend®
OcuExtend® places the utmost importance on animal welfare and respecting the rights of all living creatures. In all of our reported research studies, no animals were harmed or killed. Animal welfare and ethical considerations have been at the forefront of our work throughout the research and development process.
OcuExtend®
Rahesh Darou Novin, a pioneering research and development company, is at the forefront of innovative ocular drug delivery products under the brand 'OcuExtend®'
Rahesh Darou Novin’s OcuExtend® systems can administer medication for 3-30 days with a single application. These systems do not require anesthesia or sedation for administration
OcuExtend®
Timo/OcuExtend® for treatment of glaucoma
The prepared Timolol inserts demonstrated greater efficacy than commercial eye drops in reducing intraocular pressure (IOP) over an extended period. They can enhance patient compliance by decreasing the frequency of administration in glaucoma treatment, achieving a reduction in IOP of nearly 5 mmHg over six days, which is more favorable compared to the rapid release of marketed eye drops within four hours. Additionally, no significant signs of irritation or tissue damage were observed following the administration of the formulation.
OcuExtend®
Dual drug-loaded AmiVan-OcuExtend® for Ophthalmic sustained delivery of Amikacin/ Vancomycin
OcuExtend®
Efficacy of Cefta-OcuExtend® in Treating Pseudomonas aeruginosa-Induced Corneal Ulcers
Future:
Currently, Rahesh Darou Novin is completing the clinical studies for the 'OcuExtend®’ system.
studies will continue until the approval for entry into the human pharmaceutical market is obtained.
Follow Us On
© Your company Name. All rights reserved.
